Various studies have detailed the role of E2F proteins in both transcription activation and repression. Further study has shown that distinct promoter elements, but comprising the same E2F-recognition motif, confer positive or negative E2F control and that this reflects binding of either activator or repressor E2F proteins, respectively. We now show that the specificity of binding of an activator or repressor E2F protein is determined by adjacent sequences that bind a cooperating transcription factor. We propose that the functional E2F element is a module comprising not only the E2F-binding site but also the adjacent site for the cooperating transcription factor.
Introduction
The control of normal cell growth and cell fate requires a coordination of cell signaling events leading to the regulation of the transcription of key genes affecting the phenotypes. One of the signaling pathways, which have a central role in the regulation of cellular proliferation, differentiation, development and apoptosis, is the retinoblastoma RB/E2F pathway (Dyson, 1998; Nevins, 1998; DeGregori and Johnson, 2006) . Indeed, E2Fs are critical for the control of genes associated with DNA replication and mitosis, and the control of these transcription factors is frequently disrupted in cancer cells (Sherr, 1996; Dyson, 1998; Nevins, 1998; Ishida et al., 2001; Polager et al., 2002; Ren et al., 2002; Sears and Nevins, 2002; Zhu et al., 2004) . The E2F family of transcription factors consists of eight members (E2F1-8) (DeGregori and Johnson, 2006) .
Earlier studies suggest that the individual members of the E2F family have independent roles, including evidence that the E2F genes exhibit distinct expression profiles during the cell cycle, individual members of the E2F family associate with different members of the Rb family, the E2F1, E2F2 and E2F3a proteins function primarily as transcriptional activators, whereas the E2F3b, E2F4, E2F5, E2F6, E2F7 and E2F8 proteins function primarily as transcriptional repressors, and the abilities of the individual members of the E2F family to mediate proliferation, to regulate differentiation and development, and to induce apoptosis differ (Trimarchi et al., 2001; Sears and Nevins, 2002; Di Stefano et al., 2003; de Bruin et al., 2003; Christensen et al., 2005; Logan et al., 2005; DeGregori and Johnson, 2006) . For example, earlier studies have shown that E2F1 and E2F3 are both required for cell cycle entry, whereas E2F3 alone has an important role in successive cell cycle entries in asynchronously growing cells (Kong et al., 2007) . Consistent with these distinct roles, genes whose regulation is affected by knockdown of E2F1 versus E2F3 differ markedly (Kong et al., 2007) . In addition, E2F1 possesses a unique ability to induce apoptosis (Kowalik et al., 1995 (Kowalik et al., , 1998 DeGregori et al., 1997; Vigo et al., 1999; Ziebold et al., 2001; Nevins, 2003, 2006; Hallstrom et al., 2007) . These distinct signaling events mediated by E2F1 are reflected in the activation of distinct sets of genes (Hallstrom et al., 2007) . These observations point to the critical role of specificity of transcriptional control by the E2F proteins and raise the important question of the mechanism by which related but distinct family members differentially control transcription of target genes. Of course, the E2Fs are but an example of the broader question of transcriptional control specificity and, in particular, the mechanisms by which transcription factors identify functional binding sites within the human genome.
One possible mechanism that could be used to achieve transcriptional specificity within the E2F family of transcription factors is the recognition of slightly different nucleotide sequences by E2F family members. Although there is one report suggesting that the E2F proteins might recognize distinct DNA sequences in promoters (Tao et al., 1997) , an earlier study of the crystal structure of an E2F4-DP2 complex bound to the adenovirus E2 promoter has revealed that the amino acids of the E2F and DP proteins that contact the E2F consensus DNA-binding site are conserved among all of the E2F and DP family members (Zheng et al., 1999) . Moreover, in vitro site-selection experiments and in vivo chromatin immunoprecipitation (ChIP) experiments have also shown that different E2F-DP complexes recognize the same E2F-binding sequences (Takahashi et al., 2000; Wells et al., 2000; Trimarchi and Lees, 2002) . It is therefore unlikely that the DNA sequence recognized by E2F is solely responsible for distinguishing E2F target genes.
An alternative basis for promoter specificity is the concept of combinatorial transcription control in which pairs of transcription factors function in combination with one another to synergistically activate the given promoters (Stanojevic et al., 1991; Yamamoto et al., 1998) . In this scenario, the specificity is determined not just by a single DNA-binding element but rather by the combined sequence and context of the elements. Our earlier study has suggested a mechanism for transcriptional specificity among the E2F family of transcription factors that involves distinct protein-protein interactions to regulate cellular target genes. This includes roles for the YY1 and TFE3 transcription factors in interactions with activator E2Fs to form specific promoter complexes important for the expression of genes at G1/S (Schlisio et al., 2002; Giangrande et al., 2003 Giangrande et al., , 2004 . Combinatorial gene control may not only be an important mechanism through which specific members of the E2F family activate particular E2F target genes, but also it may be an important mechanism through which specific members of the E2F family repress particular E2F target genes. As an example, an earlier study has shown that the repressor E2F4 and the protein that binds to the CHR element have a role in combinatorial gene control of the Cdc2 gene .
We have now focused on the mechanisms underlying the specificity of E2F transcription activation versus repression by directly showing that the specificity of binding of an activator or repressor E2F protein is dictated by adjacent promoter sequences that bind cooperating transcription factors.
Results
Distinct E2F-binding elements determine positive and negative E2F transcription control Earlier studies have shown that specific members of the E2F family mediate either transcriptional activation or transcriptional repression (Trimarchi and Lees, 2002) . For instance, the E2F1-3 proteins are identified as activators, whereas the E2F4 and E2F5 proteins mediate transcription repression. Importantly, ChIP assays have shown that these distinct classes of E2Fs also bind to distinct promoter sequences (Schlisio et al., 2002; Araki et al., 2003; Zhu et al., 2004) . As an example, only the activator E2Fs (E2F2 and E2F3) bind to the positiveacting -1 E2F site within the Cdc6 promoter (Schlisio et al., 2002) (Figure 1a ). In addition, activator E2Fs (E2F1, E2F2 and E2F3) have been shown to bind to the positive-acting distal E2F site within the Cdc2 promoter, whereas the repressor E2F (E2F4) binds to the negativeacting proximal E2F site within the Cdc2 promoter (Figure 1a ). Although it is clear from these studies that there are distinct interactions between specific members of the E2F family of transcription factors and distinct E2F-binding sites within E2F target gene promoters, the mechanism underlying such a transcriptional specificity is not understood.
One possible mechanism by which specific E2Fs could distinguish between particular E2F-binding sites could involve the recognition of distinctions among the nucleotide sequences of the E2F-binding sites within the promoters. To address this directly, we used electrophoretic mobility shift assays to measure the binding of activator E2Fs (for example, E2F3) versus repressor E2Fs (for example, E2F4) to positive-and negative-acting E2F sites within the Cdc6 and Cdc2 promoters. As shown in Figure 1b , both E2F3 and E2F4 bind to the positive-acting (À1 E2F) site and the negative-acting (À36 E2F) site within the Cdc6 promoter. Similarly, as shown in Figure 1c , both E2F3 and E2F4 bind to the positive-acting (distal) E2F site and the negative-acting (proximal) E2F site within the Cdc2 promoter. These data show that members of the E2F family of transcription factors are capable of binding to each of the E2F-binding sites and that the subtle distinctions in the nucleotide sequences of E2F-binding sites do not appear to have a role in distinguishing E2F-binding sites within promoters.
Specificity of promoter interaction by an E2F activator or repressor is determined by promoter context
An alternate mechanism by which specific E2Fs could distinguish between particular E2F-binding sites could involve an interaction with transcription factors that are binding partners of specific E2Fs. Earlier ChIP assays showing a role for such interactions in allowing the formation of functional complexes in vivo suggest that binding partners of specific E2Fs could direct specific activator or repressor E2Fs to particular E2F-binding sites. For instance, E2F3 was shown to interact specifically with the TFE3 transcription factor to allow the formation of a functional promoter complex with the DNA polymerase ap68 promoter (Giangrande et al., 2003) . To directly address the contribution of cooperating transcription factors in directing specific E2Fs to particular E2F sites within the promoters of E2F target genes, we used ChIP assays with transfected plasmidborne promoter constructs. Specifically, these assays were performed to assess whether changing the partner element co-occurring with an E2F-binding site in a given promoter could result in changing the specificity of the individual member of the E2F family that interacts with the particular E2F-binding site in the given promoter.
An earlier study has shown that activator E2Fs (E2F2 and E2F3) bind to the positive-acting -1 E2F site in the Cdc6 promoter (Schlisio et al., 2002) . As shown by the data in Figure 2a , we show that E2F4, but not E2F3, binds to the negative-acting À36 E2F site within the Cdc6 promoter. This promoter thus provides a model for studying the interactions between specific members of the E2F family and particular E2F sites within a given promoter. We have used ChIP assays to examine the interactions of E2Fs on transfected plasmid-borne Cdc6 promoter constructs to determine whether the transcription factors that participate in combinatorial gene regulation with E2Fs influence specific members of the E2F family to bind to particular E2F sites within the promoter. This type of ChIP assay has been used earlier by our laboratory to evaluate the effect of promoter mutations on binding of transcription factors to promoters in vivo (Giangrande et al., 2003; Zhu et al., 2004) . T98G cells were transfected with plasmid-borne Cdc6 promoter constructs, as described below, and the cells were harvested for ChIP at a time point representing the G1/S phase of the cell cycle.
As seen in Figure 2b , the insertion of a YY1-binding site adjacent to the À36 E2F site within the Cdc6 promoter does influence the member of the E2F family that interacts with the À36 E2F site during the G1/S phase of the cell cycle, with E2F3a now preferentially interacting with the À36 E2F site within the Cdc6 promoter instead of E2F4. As shown in Figure 2c , mutation of the inserted YY1-binding site adjacent to the À36 E2F site within the Cdc6 promoter confirmed that, in the absence of a YY1-binding site, E2F4 preferentially interacts with the À36 E2F site within the Cdc6 promoter during the G1/S phase of the cell cycle. These data suggest that transcription factors that participate in combinatorial gene regulation with E2Fs direct specific E2F family members to particular E2F sites within E2F target genes.
As a second example of E2F specificity, we have focused on the control of the G2/M-regulated Cdc2 gene in which an earlier study has shown a distinct binding of activator E2Fs to a positive-acting distal E2F site and binding of a repressor E2F to a negative-acting proximal E2F element . We have again used ChIP assays to examine the interactions of E2Fs on transfected plasmid-borne promoter constructs, in this case using the Cdc2 promoter.
As seen in Figure 3a , and as shown earlier , E2F4 interacts with the negative-acting proximal (Tommasi and Pfeifer, 1995; Yan et al., 1998; Schlisio et al., 2002; Zhu et al., 2004) . (b and c) Binding of E2F3 and E2F4 to E2F sites within the Cdc6 promoter and Cdc2 promoter, respectively. EMSAs used to detect the binding of in vitro transcribed and translated HA-E2F3 and HA-E2F4 proteins to a Cdc6 promoter fragment containing the À1 E2F site, to a Cdc6 promoter fragment containing the À36 E2F site, to a Cdc2 promoter fragment containing a wild-type distal E2F site and a mutated proximal E2F site, or to a Cdc2 promoter fragment containing a wildtype proximal E2F site and a mutated distal E2F site, as indicated next to each gel. Lane 1 depicts the control reaction containing only the radiolabeled DNA probe. Lanes 2 and 4 depict binding reactions using 4 mg of in vitro transcribed and translated HA-E2F3 or HA-E2F4 protein, respectively. Lanes 3 and 5 depict antibody supershift assays using 0.2 mg of a polyclonal antibody against HA. EMSA, electrophoretic mobility shift assay; HA, hemagglutinin.
E2F site within the Cdc2 promoter during the G1/S phase of the cell cycle. As seen in Figure 3b , insertion of a YY1-binding site adjacent to the proximal E2F site within the Cdc2 promoter does influence the member of the E2F family that interacts with the proximal E2F site during the G1/S phase of the cell cycle, with E2F3a now preferentially interacting with the proximal E2F site within the Cdc2 promoter instead of E2F4. As shown in Figure 3c , mutation of the inserted YY1-binding site adjacent to the proximal E2F site within the Cdc2 promoter confirmed that, in the absence of a YY1-binding site, E2F4 preferentially interacts with the proximal E2F site within the Cdc2 promoter during the G1/S phase of the cell cycle. Taken together, these data provide direct evidence that the specificity for interaction of a particular E2F with a promoter element is dictated by the promoter context involving adjacent transcription factor-binding elements.
Extending the concept of combinatorial E2F control Given the role of combinatorial interactions in defining the specificity of E2F function, we would predict that sets of genes within the human genome exist that have promoters containing co-occurring binding sites for E2F and the binding partner that determines the specificity of the E2F activator or repressor that binds to the E2F element. We have sought to address this in the context of the role of YY1 as a partner for the E2F3 activator.
To do so, we examined the effect of knockdown of either E2F3 or YY1 on the expression level of the predicted target genes. As shown in Figure 4a , small interfering RNA duplexes targeting E2F3 and YY1 were effective in reducing E2F3 and YY1 protein levels, respectively. An analysis of the genes predicted to be regulated jointly by E2F3 and YY1 revealed a strong association with replication and/or cell cycle functions, based on the reduced expression observed in cells transfected with both E2F3 and YY1 small interfering RNAs (Figure 4b) . To verify that genes predicted to be jointly regulated by the combined action of E2F3 and YY1 were indeed direct targets, we made use of ChIP assays to measure the interaction of E2F3 and YY1 with the promoters of genes most affected by the joint knockdown (ENSA and ICMT ). As shown in Figure 4c , ChIP analyses reveal that E2F3 and YY1 interact with the ENSA and ICMT promoters. As a control, no binding of either E2F3 or YY1 was observed with the albumin promoter. Taken together, the results show a broad array of genes whose expression is dependent on functional E2F3 and YY1, coinciding with the presence of E2F and YY1 elements in the promoters and joint binding of the two proteins to these elements. This supports the concept of selective activation of E2F target genes through combinatorial gene control across the human genome.
Discussion
Although the recognition of specific DNA sequences is critical to the specificity of action of transcription factors, a number of observations suggest that this is not sufficient. In particular, most transcription factors recognize DNA sequences of 5-8 bp in length, which is not sufficient information to identify unique promoter sequences within a three billion base pair genome. Various studies point to a role for protein-protein interactions as one mechanism to increase the specificity of promoter recognition (Pilpel et al., 2001; Smale, 2001) . This mechanism of combinatorial gene regulation involving the cooperative binding of two transcription factors results in the potential to increase the complexity of DNA recognition, and thus adds specificity of promoter selection (Yamamoto et al., 1998) . One of the first such examples of combinatorial gene regulation can be seen with respect to the control of herpes simplex virus transcription in which an interaction of the viral VP16 protein with the Oct-1 and HCF-1 cellular transcription factors creates a complex that recognizes a unique 9-bp DNA sequence (TAATGARAT) found in herpes virus immediate-early promoters (Wysocka and Herr, 2003) . In essence, the functional transcription factor is the complex of these proteins, recognizing not just the individual elements but also the combined elements in the form of a transcription module. Importantly, this concept provides a further opportunity for combinatorial action in which the elements of the complex can interact with other partners to achieve additional specificities of transcription control.
The evolution of the E2F family can be seen as an example of the complexity of transcriptional control in which individual members of the E2F family participate in the activation of distinct sets of genes with distinct functional outputs (Muller et al., 2001 ). This includes both positive and negative control of these genes by distinct E2F family members (Schlisio et al., 2002; Zhu et al., 2004) . As an example, E2F1 and E2F3 are critical for the activation of genes not only at the G1/S phase of the cell cycle to generate DNA-replication activities but also at the G2/M phase of the cell cycle to produce the mitotic gene functions (Dyson, 1998; Nevins, 1998; Ishida et al., 2001; Polager et al., 2002; Ren et al., 2002; Zhu et al., 2004) . In addition, although E2F1 activates a collection of genes important for cellular proliferation, it also signals an apoptotic program (DeGregori et al., 1997; Bates et al., 1998; Irwin et al., 2000; Lissy et al., 2000; Stiewe and Putzer, 2000; Moroni et al., 2001; Croxton et al., 2002; Nahle et al., 2002; Rogoff et al., 2004; Hallstrom and Nevins, 2006) . In each case, distinct sets of genes are activated by the individual E2Fs under different circumstances. The Cdc6 gene is an example of an E2F target gene regulated at G1/S and critical for the initiation of DNA replication (Yan et al., 1998) . Our earlier study has described a model for the control of Cdc6 in which RYBP acts as a bridging protein within a ternary complex, involving E2F2/3, RYBP and YY1, which is required for the activation of the promoter (Schlisio et al., 2002) . Thus, YY1 is one of the distinct partner proteins that has a role in imparting specificity of transcription control within the E2F family.
In most instances, the genes positively regulated by the activator E2Fs are also subject to negative control by the repressor E2F proteins. In particular, the negative control is an active process by which distinct E2F family members actively repress the transcription of target genes. An earlier study has suggested that distinct promoter elements are involved in the positive or negative control. For example, as shown earlier, the Cdc2 promoter contains two E2F sites, a distal E2F site, which is involved in positively controlling the promoter and to which the activator E2Fs (E2F1-3) bind, and a proximal E2F site, which is involved in negatively controlling the promoter and to which the repressor E2F (E2F4) binds .
The study we present here now shows that these distinctions are dictated not by the E2F elements, but rather by the context of the E2F elements, with the presence of elements for interacting proteins determining which form of an E2F forms the complex and thus the consequence of the interaction. Thus, at least part of the specificity of transcription control within the E2F family appears to reflect a mechanism similar to that described for VP16, with interaction with distinct partner proteins imparting specificity of transcription control. Such a mechanism for specificity of E2F function implies that protein-protein interactions direct particular E2Fs to specific subsets of E2F target gene promoters, allowing particular E2Fs to regulate different target genes, thus resulting in distinct functional roles for E2Fs. In addition, this mechanism for specificity of E2F function also implies that proteins that participate in combinatorial gene regulation with E2Fs appropriately direct activator or repressor E2Fs to particular E2F sites involved in positive or negative control of E2F target genes, respectively.
Taken together, we believe that this study provides strong evidence for the role of transcription factor interactions in the determination of specificity of function, particularly with respect to the role of individual E2F family members to impart positive or negative control. When combined with earlier studies that point to a role for such interactions in determining the specificity of individual E2F family members in the activation of distinct sets of genes, we suggest that this represents a more general mechanism for providing the specificity of transcription factor function.
Materials and methods

Cell culture
Human embryonic kidney cells (HEK293 cells) and human ganglioblastoma cells (T98G cells) were grown in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.
Plasmid constructions
To generate the Cdc6 promoter construct containing an inserted YY1-binding site adjacent to the À36 E2F-binding site, site-directed mutagenesis was performed using the QuikChange Site-Directed Mutagenesis Kit from Stratagene (La Jolla, CA, USA). The Cdc6 promoter construct containing a mutated À1 E2F site (Yan et al., 1998) was mutagenized using the following mutagenic primers: 5 0 -TCAGAATC GAGGCCGGGCCATTCGGCTTTGGCGGGAGG-3 0 and 5 0 -AGTCTTAGCTCCGGCCCGGTAAGCCGAAACCGCC CTCC-3 0 . To generate the Cdc6 promoter construct containing an inserted mutated YY1-binding site adjacent to the À36 E2F-binding site, the aforementioned plasmid was mutagenized using the following mutagenic primers: 5 0 -TCAGAATC GAGGCCGGGCGGTTCGGCTTTGGCGGGAGG-3 0 and 5 0 -AGTCTTAGCTCCGGCCCGCCAAGCCGAAACCGCC CTCC-3 0 . To generate the Cdc2 promoter construct containing an inserted YY1-binding site adjacent to the proximal E2F site, the hcdc2-dE2Fm promoter construct was mutagenized using the following mutagenic primers: 5 0 -GC CCTTTAGCGCGGTGAGGCCATTCCTGCTCGCACTTG GC-3 0 and 5 0 -GCCAAGTGCGAGCAGGAATGGCCTCA CCGCGCTAAAGGGC-3 0 . To generate the Cdc2 promoter construct containing an inserted mutated YY1-binding site adjacent to the proximal E2F site, the aforementioned plasmid was mutagenized using the following mutagenic primers: 5 0 -G CCCTTTAGCGCGGTGAGGCGGTTCCTGCTCGCACTT GGC-3 0 and 5 0 -GCCAAGTGCGAGCAGGAACCGCCTCA CCGCGCTAAAGGGC-3 0 . All constructs were confirmed by DNA sequencing.
Electrophoretic mobility shift assays HA-E2F3 and HA-E2F4 (Schlisio et al., 2002) were in vitro transcribed and translated using the TNT Quick Coupled Transcription/Translation System from Promega (Madison, WI, USA). DNA probes were generated by PCR amplification. For the Cdc6 promoter, the template used was the minimal Cdc6 promoter region (Schlisio et al., 2002) and the primers used were as follows: to generate the À1 E2F site probe 5 0 -CCGGAA TTCGGTGGGAACGCTGTGGCC-3 0 and 5 0 -CCCAAGCT TACAGCGGCAGCAGCAAAC-3 0 , and to generate the À36 E2F site probe 5 0 -CCGGAATTCGTGACTACAGCCAATC AG-3 0 and 5 0 -CCCAAGCTTCGAATGGCCACAGCGTTC-3 0 . For the Cdc2 promoter, to generate the distal site probe, the template used was hcdc2-pE2Fm and the primers used were 5 0 -CCGGAATTCTGCTTTTTCTCTAGC CGC-3 0 and 5 0 -CCCAAGCTTTTGAAGCCAAGTGCGAGC-3 0 . To generate the proximal site probe, the template used was hcdc2-dE2Fm and the primers used were 5 0 -CC GGAATTCTGCTTTTTCTCTAGCCGC-3 0 and 5 0 -CCCAA GCTTTTGAAGCCAAGTGCGAGC-3 0 . PCR products were digested with EcoRI and HindIII, radiolabeled and purified using Quick Spin Columns (TE) for Radiolabeled DNA Purification from Roche (Basel, Schweiz). Electrophoretic mobility shift assays were performed as described earlier (Ikeda et al., 1996) . The polyclonal antibody a-HA (Y-11) from Santa Cruz Biotechnology (Santa Cruz, CA, USA) was used in the electrophoretic mobility shift assays.
Reporter ChIP assays T98G cells were co-transfected with mutant promoter-reporter constructs and an internal control plasmid containing the b-galactosidase gene, pCMV-bgal, using SuperFect Transfection Reagent from Qiagen (Venlo, The Netherlands). Transfections were performed using 5 mg of promoter-reporter plasmid, 5 mg of internal control plasmid, 60 ml of SuperFect and 700 ml of Optimem (Invitrogen, Carlsbad, CA, USA). After incubation for 20 min, the transfection mix was added to the cells and incubated for 6 h at 371C. Cells were recovered overnight at 371C in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. Cells were then split 1 to 3 into starvation medium (Dulbecco's modified Eagle's medium containing 0.1% fetal bovine serum) and starved for 48 h. After starvation, cells were brought to the G1/S phase of the cell cycle by growth in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 1 mm hydroxyurea for 18 h. Cells were harvested 18 h after HU addition and reporter ChIP experiments were carried out as described earlier , but with the following modification. Immunoprecipitated chromatin was detected by quantitative PCR using the QuantiTect SYBR Green PCR Kit from Qiagen and the 7900HT Fast Real-Time PCR System from Applied Biosystems (Foster City, CA, USA). Primers used in the quantitative PCR were as follows: for the Cdc6 promoter 5 0 -GTGACTACAGCCAATCAG-3 0 and GLprimer2 from Promega, for the Cdc2 promoter 5 0 -GCTTGCGCTCGCACT CAGTTGGCG-3 0 and GLprimer2 from Promega and for the b-galactosidase promoter 5 0 -ACTGGCAGATGCACGGTTA CGATG-3 0 and 5 0 -CACATCTGAACTTCAGCCTCCAG-3 0 . Antibodies used in the reporter ChIP experiments were as follows: anti-E2F3 sc879 from Santa Cruz Biotechnology, anti-E2F4 sc1082 from Santa Cruz Biotechnology and ImmunoPure Rabbit Gamma Globulin from Pierce (Waltham, MA, USA). ChIP data were analysed as described by Aparicio et al. (2005) .
Endogenous ChIP assays
Asynchronously growing HEK293 cells were harvested and endogenous ChIP experiments were carried out as described earlier , but with the following modification. Immunoprecipitated chromatin was detected by quantitative PCR using the QuantiTect SYBR Green PCR Kit from Qiagen and the 7900HT Fast Real-Time PCR System from Applied Biosystems. Primers used in the quantitative PCR were as follows: for the ENSA promoter 5 0 -GGTCCTTGT GGCTCACTCTC-3 0 and 5 0 -GGGCAATGACGTAACGAT CT-3 0 , for the ICMT promoter 5 0 -GGGACTAAGTTTGGAC AGACG-3 0 and 5 0 -GGGAAGTGGTGGGAGAAGTC-3 0 and for the albumin promoter 5 0 -TGGGGTTGACAGAAGAGA AAAGC-3 0 and 5 0 -TACATTGACAAGGTCTTGTGGAG-3 0 . Antibodies used in the endogenous ChIP experiments were as follows: anti-E2F3 sc879 from Santa Cruz Biotechnology, anti-YY1 sc7341 Â from Santa Cruz Biotechnology and ImmunoPure Rabbit Gamma Globulin from Pierce. ChIP data were analysed as described by Aparicio et al. (2005) .
Small interfering RNA assays
Asynchronously growing HEK293 cells were transfected using DharmaFECT Reagent 2 from Dharmacon (Waltham, MA, USA) with the following small interfering RNAs from Dharmacon: human YY1 siGENOME duplex D-011796-06 and D-011796-07, or human E2F3 siGENOME duplex D-003261-05, D-003261-06, D-003261-07 and D-003261-09. We performed three replicates of each knockdown. Cells were harvested after 48 h. Nuclear extracts were prepared from half of the cells and used in western blot assays to confirm knockdown of the respective proteins. Antibodies used in the western blot assays were as follows: anti-YY1 sc-7341 from Santa Cruz Biotechnology, anti-E2F3 sc-878 from Santa Cruz Biotechnology and anti-a-tubulin T5168 from Sigma (St Louis, MO, USA). Total RNA was prepared from the other half of the cells using the Qiashredder and the RNeasy Mini Kit from Qiagen. RNA quality was confirmed by an Agilent 2100Bioanalyser (Santa Clara, CA, USA).
DNA microarray analysis
Affymetrix DNA microarray analysis was prepared according to the manufacturer's instructions, and targets were hybridized to the Human U133A GeneChip (Affymetrix, Santa Clara, CA). To process the microarrays, we normalized the CEL files using the MAS5 implementation in Bioconductor (Gentleman et al., 2004) . We mapped the genes to Entrez Gene records using the annotations provided by NetAFFX. We discarded unannotated genes and genes expressed at signal levels lower than 100. We then averaged the three replicates in each condition and calculated fold enrichment for a gene as the ratio of the average expression of the gene in either the E2F or YY1 knockdown to the control. Next, we downloaded the sequence of the human genome from the UCSC database and used version hg18 (Kuhn et al., 2009) . From the complete assembly, we extracted the proximal promoter of each gene, using the transcription start site annotations from both the known Gene and refFlat files. We determined the proximal promoter to be 250 bp upstream of the transcription start site to 50 bp downstream because of enrichment of predicted E2F sites in that region (data not shown). Using the promoter sequence for all annotated genes in the genome, we searched for the presence of binding sites for E2F and YY1. We defined E2F-binding sites as the sequences that match the positionspecific scoring matrix MA0024 from the JASPAR database with a P-value o0.0001 using the patser tool (Boulder, CO, USA) (Bryne et al., 2008) . For YY1, we used M00793 from TRANSFAC with a cutoff of Po0.005 (Matys et al., 2006) . To choose the matrices and cutoffs, we used the known binding sites of E2F and YY1 in the CDC6 promoter as a model. We predicted E2F-YY1 modules by identifying the predicted binding sites for E2F and YY1, with fewer than 15 bases in between the predicted sites. We did not allow overlapping of the binding sites. Using the CDC6 promoter as a model, we only accepted modules where the binding sites occurred on the same strand.
